A company-sponsored Phase 2 clinical trial to optimize the dosing and administration regimen of MGTA-145 plus plerixafor in healthy subjects
Latest Information Update: 17 Jan 2024
At a glance
- Drugs MGTA 145 (Primary) ; Plerixafor (Primary)
- Indications Stem cell mobilisation
- Focus Therapeutic Use
- Sponsors Dianthus Therapeutics; Magenta Therapeutics
- 10 Jan 2022 According to a Magenta Therapeutics media release, company expects to generate data from this healthy subjects clinical trial in the second half of 2022.
- 10 Jan 2022 Status changed from planning to recruiting, according to a Magenta Therapeutics media release.
- 20 Dec 2021 New trial record